Full title: Assessing Red Blood Cell Distribution Width in Vietnamese Heart Failure Patients: A Cross-Sectional Study Short title: Red Blood Cell Distribution Width in Heart Failure Patients

- 1 Hai Nguyen Ngoc Dang^{1,2¶}, Thang Viet Luong^{3,4¶}, Mai Thi Thu Cao³, Vinh Trung Bui³,
- 2 Thanh Thien Tran³, Hung Minh Nguyen^{5,6*}
- ³ ¹The Faculty of Medicine, Duy Tan University, Da Nang, Viet Nam
- 4 ²Cardiovascular Center, Hue Central Hospital, Hue, Viet Nam
- ⁵ ³Hue University of Medicine and Pharmacy, Hue, Viet Nam
- ⁶ ⁴Hue University of Medicine and Pharmacy Hospital, Hue, Viet Nam
- 7 ⁵Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Viet Nam
- 8 ⁶Hanoi Medical University, Hanoi, Viet Nam
- 9 *Corresponding author:
- 10 Email: mdhungnguyen@gmail.com (HMN)
- ¹¹ [¶]Hai Nguyen Ngoc Dang and Thang Luong Viet contributed equally to this work.

- 12 Author contributions:
- 13 Conceptualization: Hai Nguyen Ngoc Dang, Thang Viet Luong.
- 14 Data curation: Hai Nguyen Ngoc Dang, Thang Viet Luong.
- 15 Formal analysis: Hai Nguyen Ngoc Dang, Thang Viet Luong.
- 16 Investigation: Hai Nguyen Ngoc Dang, Thang Viet Luong.
- 17 Methodology: Hai Nguyen Ngoc Dang, Thang Viet Luong.
- 18 Supervision: Hai Nguyen Ngoc Dang, Thang Viet Luong, Hung Minh Nguyen.
- 19 Writing original draft: Hai Nguyen Ngoc Dang, Thang Viet Luong, Mai Thi Thu Cao,
- 20 Vinh Trung Bui, Thanh Thien Tran, Hung Minh Nguyen.
- 21 Writing review & editing: Hai Nguyen Ngoc Dang, Thang Viet Luong, Mai Thi Thu
- 22 Cao, Vinh Trung Bui, Thanh Thien Tran, Hung Minh Nguyen.

23 Abstract

Heart failure (HF) is a growing public health concern, with red cell distribution width (RDW) gaining recognition as a cost-effective marker for predicting HF onset and progression. This study, conducted from February 2022 to February 2024 at Hue Central Hospital, aimed to assess RDW levels in hospitalized Vietnamese HF patients and its predictive value for HF severity, involving a cross-sectional analysis of 351 patients

29	categorized into HF and non-HF groups. HF patients exhibited higher median RDW
30	levels (14.90% [13.70% - 17.00%]) compared to non-HF individuals (13.10% [12.23%
31	- 13.78%]). RDW was higher in HF patients with left ventricular ejection fraction
32	(LVEF) < 50% (15.30%) than LVEF \geq 50% (14.70%). ROC curve analysis for acute
33	heart failure (AHF) prediction yielded an AUC of 0.651 ($p < 0.001$), with a cutoff point
34	of 13.85%, sensitivity of 86.05%, and specificity of 36.94%. Elevated RDW levels were
35	associated with HF risk (OR: 1.844, $p < 0.001$) and AHF (OR: 3.612, $p < 0.001$).
36	Multivariate analysis identified associations between RDW and hemoglobin (Hb) (β =
37	2.431, p = 0.040) and hematocrit (HCT) (β = -3.355, p = 0.007) in HF. RBC and RDW
38	> 13.85% were independent risk factors for AHF. This suggests that RDW levels can
39	serve as biomarkers for diagnosing HF and predicting its severity. Their accessibility
40	and cost-effectiveness indicate the potential utility of RDW in managing HF,
41	particularly in settings with limited resources.

42 Introduction

Heart failure (HF) represents a complex and life-threatening syndrome characterized by significant morbidity and mortality, limited functional capacity and quality of life, and substantial economic burden [1]. Additionally, HF has emerged as an increasingly critical public health concern. Given the aging population and enhanced survival rates following acute myocardial infarction, these trends are expected to persist [2]. HF has been recognized as a global pandemic, affecting an estimated 64.3 million

individuals worldwide in 2017 [3]. Despite therapeutic advancements, HF remains a
primary contributor to morbidity and mortality on a global scale [4].

The early detection and accurate diagnosis of HF are crucial for optimizing the 51 treatment and prognoses of patients with this condition. Currently, HF diagnosis relies 52 primarily on echocardiography and patients' presenting symptoms, yet there lacks a 53 definitive prognostic indicator for mortality among HF patients [5]. Biomarkers have 54 55 shown promise in enhancing predictive capabilities alongside clinical evaluation in 56 chronic heart failure (CHF) patients, although the incremental predictive value of individual biomarkers like B-type natriuretic peptide or troponin I in acute heart failure 57 (AHF) is limited [6]. However, in Vietnam, the costs associated with these tests are 58 prohibitive, and they are only available in large medical centers, presenting a significant 59 60 challenge to their widespread application.

Red cell distribution width (RDW) is a parameter that reflects the variability in red 61 blood cell size (anisocytosis), easily obtainable from a complete blood count, and 62 represents a simple, cost-effective measure [7]. RDW is increasingly recognized as a 63 marker for predicting the onset and progression of HF. In HF patients, anisocytosis may 64 65 signify a homeostatic response to the disease, potentially indicating a link between ineffective erythropoiesis and chronic inflammation [8]. Traditionally, RDW has been 66 underappreciated and primarily used to differentiate certain causes of anemia [9]. 67 However, recent clinical evidence suggests that changes in RDW are associated with the 68

69	development and adverse outcomes of stroke and cardiovascular disease [7,8,10,11].
70	Particularly in HF patients, RDW has been correlated with hospitalization rates and poor
71	prognosis [12,13]. RDW is a readily applicable blood parameter for basic healthcare
72	facilities, especially in Vietnam. Nonetheless, most existing evidence originates from
73	regions such as the United States, Europe, Japan, and China, excluding Vietnam.
74	Therefore, this study aims to investigate RDW levels in hospitalized Vietnamese

HF patients and assess the predictive ability of RDW for the severity of HF in thispopulation.

77 Materials and methods

78 Study population

A cross-sectional study was conducted at Hue Central Hospital from February 2022 79 to February 2024, involving 351 patients categorized into two groups: those with HF 80 and those without (see Fig 1). CHF and AHF were defined and classified based on the 81 criteria outlined in the guidelines for the diagnosis and treatment of AHF and CHF of 82 the European Society of Cardiology [14]. The control group consisted of patients with 83 no history or symptoms of HF, LVEF \geq 50%, and NT-proBNP < 125 pg/mL. 84 Additionally, patients who had received blood transfusions or iron supplementation 85 during hospitalization and those with a positive osmotic fragility test were excluded 86 from the study. The project received approval from Hue Central Hospital and the 87

Institutional Review Board of Duy Tan University (No: Đ23-24Y3-2) and adhered to
the principles of the Declaration of Helsinki (2013 version).

90 Fig 1. The research flowchart divides the research subjects into subgroups under

91 **the group.** HF: heart failure; CHF: chronic heart failure; AHF: acute heart failure.

92 Data collection

93 The baseline evaluation of the patients encompassed demographic characteristics and clinical assessments, including medical history (hypertension, diabetes mellitus, 94 dyslipidemia, coronary artery disease, chronic kidney disease, valvular heart disease, 95 96 liver disease, and cardiac arrhythmias, as well as medication usage). Additionally, other clinical data such as body mass index (BMI), waist-hip ratio, heart rate, systolic blood 97 98 pressure (SBP), diastolic blood pressure (DBP), and New York Heart Association 99 classification (NYHA) were collected. These details were routinely collected upon admission and throughout hospitalization, utilizing a pre-established registry 100 questionnaire. 101

The echocardiographic procedure adhered to the guidelines outlined by the American Society of Echocardiography for conducting a comprehensive transthoracic echocardiographic examination in adults, performed by expert echocardiographers [15].

105 The laboratory analyses were performed on fasting venous blood specimens and 106 encompassed: brain natriuretic peptide, red blood cell count, hematocrit, hemoglobin, mean cell volume, mean cell hemoglobin content, mean cell hemoglobin concentration,
platelet count, alanine aminotransferase, aspartate transaminase, glucose, urea, highsensitivity troponin T, hemoglobin A1c, total cholesterol, triglyceride, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density
lipoprotein cholesterol, potassium level, sodium level, chloride level, and estimated
glomerular filtration rate using CKD-EPI 2021 (eGFR, mL/min per 1.73 m²) [16].

113 **RDW measurement**

Blood samples were collected from 2 mL of the peripheral vein using an ethylene 114 diamine tetraacetic acid (EDTA) tube within 6 hours after admission and analyzed using 115 the Sysmex XS-1000i automated hematology analyzer (Japan), located in the 116 117 Hematology Department of Hue Central Hospital. RDW index was derived from the 118 complete blood count obtained upon patients' admission to the hospital. Two parameters of RDW were calculated to measure the extent of anisocytosis: the standard deviation 119 (SD) and the coefficient variation (CV). RDW-CV is widely investigated and is 120 121 calculated according to the following formula: RDW-CV = (SD of erythrocyte)122 volume/mean corpuscular volume) \times 100. The normal reference range for RDW in the 123 hospital laboratories that participated in the study was 11.5 - 15% with an intra-assay variation of 2.38% and an inter-assay variation of 1% [13]. In this study, we reported 124 RDW-CV and used RDW to represent it. 125

126 Fig 2. The RDW is found by the RDW-CV formula, 1 standard deviation divided

127 by MCV. RDW-CV: red blood cell distribution width-coefficient of variation. RBC:

red blood cell. SD: standard deviation. MCV: mean corpuscular volume.

129 Statistical analysis

All statistical analyses were performed using SPSS Version 26 (IBM, New York, 130 United States), MedCalc Software Version 22.019 (MedCalc Software, Ostend, 131 Belgium), and GraphPad Prism Version 10 (GraphPad Software, Boston, United States). 132 133 Data normality was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Normally distributed continuous variables were presented as mean \pm standard deviation, 134 135 while non-normally distributed variables were described as median values with interquartile ranges. Categorical variables were reported as frequencies and percentages. 136 Fisher's exact test was employed to assess intergroup differences in categorical 137 138 variables, while differences in continuous variables were analyzed using either the 139 unpaired T-test or the Mann-Whitney U test, as appropriate. Missing data were excluded 140 from the analyses. Spearman's correlation coefficient (r) and its corresponding p-value 141 were calculated to explore the correlation between continuous variables. The area under the curve (AUC) was determined using the Wilson/Brown method to predict AHF. AUC 142 comparison was conducted to evaluate the diagnostic performance of RDW compared 143 to other biochemical tests, employing the Hanley and McNeil method [17]. 144 145 Multivariable linear regression was used to evaluate the associations between clinical

factors and left left atrium phasic strain and left atri left atrioventricular coupling index, respectively. Clinical confounding factors and variables that were significant (p < 0.05) in the univariate analysis were included in the multivariable model. To prevent multicollinearity among the univariate variables, a variance inflation factor of 5 was applied. Univariate logistic regression calculated odds ratios to predict HF. All statistical tests were two-sided, with a significance level of < 0.05.

152 **Results**

153 **Baseline characteristics**

154 The study involving 351 subjects revealed significant variations in blood cell count 155 such as RBC, Hb, and RDW-CV between HF and non-HF patients. Detailed information

regarding these indices is presented in **Table 1**.

157 **Table 1. Baseline characteristics of the study groups.**

Characteristics	Non-HF (n= 152)	HF (n = 199)	p-value
Ba	seline demographic and	clinical features	
Age (Years)	66.6 ± 12.1	70.1 ± 14.1	0.008
Female	115 (75.7)	119 (59.8)	0.002
Heart rate (bpm)	82 [76 - 90]	81 [75 - 95]	0.838
SBP (mmHg)	140 [130 - 170]	130 [110 - 150]	< 0.001

DBP (mmHg)	80 [80 - 90]	80 [70 - 80]	< 0.001
BMI (kg/m ²)	22.4 [20.2 - 25.3]	21.0 [19.2 - 23.1]	< 0.001
WHR	1.0 [0.9 – 1.0]	1.0 [0.9 – 1.0]	0.681
NYHA		2 [2 - 3]	
LVEF (%)	62.5 [61.0 - 64.3]	55.0 [36.0 - 61.0]	< 0.001
Smoking	27.0 (17.8)	31.0 (15.6)	0.664
Alcohol	12.0 (7.9)	16.0 (8.0)	0.063
Diabetes	20.0 (13.2)	51.0 (25.6)	0.005
Dyslipidemia	39.0 (25.7)	66.0 (33.2)	0.158
Hypertension	116.0 (76.3)	130 (65.3)	0.034
Stent	3.0 (2.0)	47.0 (23.6)	< 0.001
CABG	0.0 (0.0)	11.0 (5.5)	0.003
Atrial fibrillation	1.0 (0.7)	39.0 (19.6)	< 0.001
Stroke	8.0 (5.3)	15.0 (7.5)	0.515
CKD	3.0 (2.0)	21.0 (10.6)	0.001
	Medication u	Isage	
Antiplatelet	17.0 (11.2)	25.0 (12.6)	0.005
Beta blockers	24.0 (15.8)	44.0 (22.1)	< 0.001
ACEi/ARB	81.0 (53.3)	59.0 (29.7)	0.299
MRA	4.0 (2.6)	42.0 (21.1)	< 0.001

ARNI	0.0 (0.0)	7.0 (3.5)	0.001
SGLT2i	4.0 (2.6)	26.0 (13.1)	< 0.001
Digoxin	0.0 (0.0)	7.0 (3.5)	0.001
	Laboratory para	meters	
WBC (10 ⁹ /L)	7.8 [6.5 - 9.6]	7.6 [6.0 - 9.9]	0.742
RBC (10 ¹² /L)	4.5 [4.2 - 4.7]	3.8 [3.3 - 4.3]	< 0.001
Hb (g/dL)	13.1 [12.1 – 14.0]	10.9 [8.7 - 12.5]	< 0.001
HCT (%)	39.5 [37.5 - 41.5]	33.5 [27.3 - 38.2]	< 0.001
MCV (fL)	89.4 [86.1 - 92.6]	88.3 [81.1 - 92.8]	0.088
MCH (pg)	29.9 [28.8 - 30.9]	29.0 [26.1 - 30.6]	0.002
MCHC (g/dL)	33.2 [32.5 - 34.1]	32.6 [31.7 - 33.4]	< 0.001
RDW-CV (%)	13.10 [12.23 - 13.78]	14.90 [13.70 - 17.00]	< 0.001
PLT (10 ⁶ /µL)	251 [215 - 294]	230 [184 - 287]	0.006
MPV (fL)	9.4 [8.3 - 9.9]	8.7 [8.0 - 9.5]	0.001
Glucose (mg/dL)	6.3 [5.3 - 7.8]	6.4 [5.3 - 7.7]	0.614
HbA1c (%)	6.3 [5.6 - 8.2]	6.5 [5.8 - 8.1]	0.634
AST (U/L)	24.0 [19.3 - 31.4]	29.7 [21.5 - 41.2]	0.002
ALT (U/L)	22.5 [15.4 - 33.2]	22.0 [14.1 - 31.8]	0.567
Cholesterol (mg/dL)	5.1 ± 1.1	4.4 ± 1.1	< 0.001
Triglyceride (mg/dL)	1.5 [1.0 - 2.4]	1.2 [0.9 - 1.8]	< 0.001

HDL-C (mg/dL)	1.3 ± 0.3	1.2 ± 0.3	0.013
Non-HDL-C (mg/dL)	3.8 ± 1.0	3.2 ± 1.0	< 0.001
LDL-C (mg/dL)	3.2 [2.5 - 3.8]	0.9 [0.6 - 2.4]	< 0.001
Urea (mg/dL)	4.7 [3.7 - 6.2]	6.3 [5.0 - 8.6]	< 0.001
Creatinine (mg/dL)	67 [55 - 79]	84 [61 - 121]	< 0.001
Potassium (mEq/L)	3.4 [3.2 - 3.8]	3.7 [3.3 - 4.2]	< 0.001
Sodium (mEq/L)	138 [134 – 139]	136 [134 - 140]	0.278
Chloride (mEq/L)	101 [99 - 103]	101 [97 - 105]	0.478
hs-TnT (ng/L)	7.0 [6.0 – 11.0]	18.5 [9.0 – 31.5]	< 0.001
NT-proBNP (pg/mL)	64 [32 - 99]	1807 [487 - 8353]	< 0.001

Values are presented as mean \pm standard deviation, median [25th interquartile - 75th 158 interquartile], or number (%) as appropriate. SBP: systolic blood pressure; DBP: 159 diastolic blood pressure; BMI: body mass index; WHR: waist hip ratio; NYHA: New 160 York Heart Association; LVEF: left ventricular ejection fraction; CABG: coronary 161 artery bypass graft; CKD: chronic kidney disease; ACEi/ARB: angiotensin-converting 162 enzyme inhibitor/angiotensin receptor blocker; MRA: mineralocorticoid receptor 163 antagonist; ARNI: angiotensin receptor neprilysin inhibitor; SGLT2i: sodium-glucose 164 cotransporter 2 inhibitor; WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; 165 HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular 166 hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-CV: red 167 blood cell distribution width coefficient of variation; PLT: platelet; MPV: mean platelet 168

volume; HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine
aminotransferase; HDL-C: high-density lipoprotein cholesterol; Non-HDL-C: nonhigh-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-B-type natriuretic
peptide.

174 Comparison of RDW among different study groups

175 We observed significantly higher RDW-CV levels in AHF patients compared to

176 the non-HF group. Additionally, HF patients with preserved ejection fraction had lower

177 RDW-CV values compared to those with EF < 50%. Moreover, RDW levels increased

178 with higher NYHA classifications. Detailed findings are illustrated in Fig 3.

179 Fig 3. Comparison of RDW-CV among different study groups. (A) Illustrates the

180 comparison of RDW-CV among Non-HF, CHF, and AHF groups. (B) Compares RDW-

181 CV in HF patients with LVEF \geq 50 and < 50. (C) Compares RDW-CV in NYHA I/II

and NYHA III/IV groups. RDW-CV: red blood cell distribution width -coefficient of

183 variation; HF: heart failure; CHF: chronic heart failure; AHF: acute heart failure; LVEF:

184 left ventricular ejection fraction; NYHA: New York Heart Association.

The predictive value of RDW for AHF

The prognostic significance of AHF in patients with CHF, as determined by RDW, is elucidated through ROC analysis, yielding an AUC of 0.651 (p < 0.001). The

188 identified cutoff point stands at 13.85%, boasting a sensitivity of 86.05% and specificity of 36.94%. Comparative analysis between RDW and hs-TnT reveals a superior AUC 189 for the latter. Nevertheless, employing the Hanley and McNeil method to discern the 190 191 statistical significance between these AUCs, we find the discrepancy to be nonsignificant (p > 0.05). Conversely, RDW exhibits statistically significant differences 192 (p < 0.05) when compared to WBC, PLT, and MCV. Fig 4 further illustrates the 193 predictive utility of AHF across various indices, including WBC, PLT, MCV, and hs-194 TnT. 195

Fig 4. Receiver operating characteristic curves for predicting AHF among HF patients. (A-E) Depict the ROC curves of RDW-CV, WBC, PLT, MCV, and hs-TnT,

respectively. (F) Compares the differences between the AUCs of RDW-CV, WBC, PLT,

199 MCV, and hs-TnT using the Hanley & McNeil method. ROC: receiver operating

200 characteristic; AUC: area under the curve; RDW-CV: red blood cell distribution width

201 coefficient of variation; WBC: white blood cell; hs-TnT: high-sensitivity troponin T;

202 PLT: platelet; MCV: mean corpuscular volume; AHF: acute heart failure.

203 Correlation analysis of RDW and clinical, subclinical indices in HF

204 patients

There is a positive correlation between the RDW-CV index and NT-proBNP and hs-TnT. Conversely, there is a negative correlation between the RDW-CV index and GFR. Furthermore, other parameters are clearly depicted in the heat map (see **Fig 5**).

Fig 5. The heat map shows RDW-CV's correlation with clinical and subclinical 208 indices in HF patients. HR: heart rate; SBP: systolic blood pressure; DBP: diastolic 209 blood pressure; BMI: body mass index; WHR: waist hip ratio; NYHA: New York Heart 210 211 Association; LVEF: left ventricular ejection fraction; WBC: white blood cell; RDW-212 CV: red blood cell distribution width coefficient of variation; PLT: platelet; MPV: mean 213 platelet volume; HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase; HDL-C: high-density lipoprotein cholesterol; Non-HDL-C: 214 non-high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; 215 216 GFR: glomerular filtration rate, K⁺: Potassium; Na⁺: sodium; Cl⁻: chloride; hs-TnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-B-type natriuretic peptide. 217

218 Linear and logistic regression analysis

Table 2 illustrates the findings from both univariate and multivariate analyses 219 conducted on RDW-CV concerning heart failure (HF). Univariate regression analysis 220 unveiled significant associations between RDW-CV and several hematological 221 222 parameters including RBC, Hb, HCT, MCV, MCH, MCHC, PLT, MPV, and GFR in 223 HF patients. Multivariate analysis further elucidated associations between RDW-CV and Hb ($\beta = 2.431$, p = 0.040) as well as HCT ($\beta = -3.355$, p = 0.007) in this patient 224 cohort. Additionally, Fig 6 portrays the outcomes of logistic regression analyses for 225 RDW-CV in HF patients, underscoring elevated RDW-CV levels as significant risk 226 227 factors for HF.

228 Table 2. Factors associated with increasing levels of RDW in linear regression.

Factors		Univariable				Multivariable			
T actors	β	p-value	95% CI		β	p-value	95% CI		
Sex	0.002	0.981	-1.027	1.052					
Age (years)	-0.028	0.698	-0.043	0.029					
HR (beats/min)	-0.082	0.253	-0.04	0.011					
BMI (kg/m ²)	-0.024	0.735	-0.212	0.15					
NYHA	0.118	0.099	-0.098	1.128					
Smoking	-0.038	0.601	-1.769	1.026					
Alcohol	0.026	0.798	-1.007	1.306					
Diabetes	-0.045	0.532	-1.531	0.793					
Dyslipidemia	0.100	0.161	-0.308	1.848					
Hypertension	-0.009	0.903	-1.138	1.005					
Stent	-0.048	0.501	-1.602	0.786					
CABG	-0.022	0.759	-2.570	1.878					
Atrial	-0.031	0.666	-1.190	0.762					
fibrillation									
Stroke	-0.058	0.417	-2.796	1.162					
СКД	-0.008	0.907	-1.748	1.553					
Antiplatelet	-0.078	0.447	-1.354	0.602					

LVEF (%)	-0.115	0.139	-0.072	0.010				
WBC (10 ⁹ /L)	-0.048	0.642	-0.143	0.089				
RBC (10¹²/L)	-0.143	0.046	-1.287	-0.012	0.906	0.070	-0.218	5.425
Hb (g/dL)	-0.456	< 0.001	-0.906	-0.514	2.431	0.040	0.119	4.936
HCT (%)	-0.405	< 0.001	-0.283	-0.146	-3.355	0.007	-2.111	-0.343
MCV (fL)	-0.446	< 0.001	-0.202	-0.113	0.950	0.512	-0.450	0.895
MCH (pg)	-0.476	< 0.001	-0.552	-0.324	-0.507	0.777	-2.513	1.884
MCHC (g/dL)	-0.314	< 0.001	-1.083	-0.434	-0.881	0.088	-3.201	0.226
PLT (10 ⁹ /L)	0.073	0.307	-0.003	0.008				
MPV (fL)	-0.113	0.114	-0.785	0.085				
GFR	-0.262	0.010	-0.059	-0.008	-0.143	0.053	-0.037	0.000
(mL/min/1.73m ²)								
NT-proBNP	0.097	0.176	0.000	0.000				
(pg/mL)								

Bold value indicates statistical significance at the p < 0.05 level. CI: confidence interval; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist hip ratio; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; CABG: coronary artery bypass graft; CKD: chronic kidney disease; ACEi/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; ARNI: angiotensin receptor neprilysin inhibitor; SGLT2i: sodium-glucose cotransporter 2 inhibitor; WBC: white

236	blood cell; RBC: red blood cell; Hb: hemoglobin; HCT: hematocrit; MCV: mean
237	corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular
238	hemoglobin concentration; RDW-CV: red blood cell distribution width coefficient of
239	variation; PLT: platelet; MPV: mean platelet volume; GFR: glomerular filtration rate;
240	NT-proBNP: N-terminal pro-B-type natriuretic peptide.

Fig 6. HF susceptibility was predicted via logistic regression using hematologic 241 242 parameters and GFR as covariates. In the univariable analysis, elevated levels of RDW-CV along with a lower level of RBC and Hb, were identified as risk factors for 243 HF. WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; HCT: hematocrit; 244 MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean 245 corpuscular hemoglobin concentration; RDW-CV: red blood cell distribution width 246 247 coefficient of variation; PLT: platelet; MPV: mean platelet volume; GFR: glomerular filtration rate. 248

Table 3 outlines independent risk factors identified in the complete blood count of AHF patients, where RBC and RDW-CV > 13.85% were recognized as independent risk factors with corresponding odds ratios of 0.313 (95% CI, 0.140-0.701; p = 0.005) and 252 2.644 (95% CI, 1.190-5.875; p = 0.017), respectively.

Table 3. Independent risk factors in complete blood count of AHF (analyzed by
logistic regression model).

	Univariable					Multiva	ltivariable	
Factors	OR ratio	p- value	95%	ó CI	OR ratio	p- value	95%	ó CI
WBC (10 ⁹ /L)	1.102	0.103	0.981	1.237				
RBC (10¹²/L)	0.458	< 0.001	0.304	0.689	0.313	0.005	0.140	0.701
Hb (g/dL)	0.737	< 0.001	0.643	0.846	0.085	0.074	0.006	1.270
HCT (%)	0.915	< 0.001	0.874	0.957	2.294	0.068	0.940	5.595
MCV (fL)	0.998	0.877	0.971	1.026				
MCH (pg)	0.966	0.339	0.899	1.037				
MCHC (g/dL)	0.760	0.009	0.619	0.934	1.397	0.385	0.657	2.967
PLT (10 ⁹ /L)	0.998	0.299	0.995	1.001				
MPV (fL)	1.145	0.271	0.899	1.458				
RDW-CV>	3.612	< 0.001	1.755	7.432	2.644	0.017	1.190	5.875
13.85%								

Bold value indicates statistical significance at the p < 0.05 level. CI: confidence interval;
OR: odd ratio; WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; HCT:
hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
MCHC: mean corpuscular hemoglobin concentration; RDW-CV: red blood cell
distribution width coefficient of variation; PLT: platelet; MPV: mean platelet volume.

RDW is a simple, fast, cost-effective hematological parameter with results routinely provided in complete blood count. Our study aimed to compare RDW values between HF patients and the control group. Additionally, it evaluated the predictive value of RDW in anticipating the likelihood of HF exacerbation. The study was conducted on 351 subjects in Vietnam, divided into two groups: those with HF and those without.

267 **RDW in HF Patients**

In our study, RDW levels in HF patients tended to be higher than in the non-HF group with p < 0.001 (**Fig 3**). Moreover, patients with elevated RDW levels were more likely to have HF compared to those with normal levels (**Fig 6**). Atac Celik et al. (2012) also found that the HF group had higher RDW compared to the control group [18]. Additionally, Yuxiang Dai et al. (2014) revealed that half of the HF patients had an RDW value above the upper limit of the normal range [19].

In our study, AHF patients had higher RDW levels compared to the CHF group and the control group (p < 0.001). Additionally, NYHA III/IV patients had higher RDW levels than NYHA I/II patients, with a significant difference observed (p = 0.02) (**Fig** 3). Similarly, Jaewon Oh et al. (2009) also found increased RDW levels in AHF patients [20].

Currently, the pathophysiological mechanism underlying the increased RDW in HF 279 patients remains incompletely understood. Some recent literature suggests that 280 inflammation, activation of the neuroendocrine system, and adrenergic activation in HF 281 282 patients may influence the erythrocyte maturation process, leading to elevated RDW [13,21,22]. Red blood cells are formed in the bone marrow from erythroid colony-283 284 forming unit-erythroid progenitors and undergo maturation into mature erythrocytes through a series of developmental stages [23]. Disruption of various biological 285 pathways, such as aging, inflammation, oxidative stress, nutritional deficiencies, 286 impaired renal function, dyslipidemia, and alterations in RBC deformability or 287 fragmentation, has been linked to impaired erythropoiesis, resulting in increased RDW 288 [13,21,24–26]. In our study, variations in hematological parameters (RBC, Hb, HCT, 289 MCV, MCH, and MCHC) were found to influence RDW outcomes. Particularly, Hb 290 and HCT emerged as two parameters exerting independent effects on RDW results in 291 the multivariable linear regression model (see Table 2). 292

Inflammation is recognized as a significant contributor to the pathophysiology of HF [27]. In HF, both cell-and cytokine-mediated inflammatory pathways are activated, causing bone marrow dysfunction and premature release of erythrocytes into the bloodstream. Inflammation inhibits bone marrow function and iron metabolism, while pro-inflammatory cytokines inhibit erythropoietin-induced erythrocyte maturation and proliferation, thus increasing RDW [28]. The correlation between RDW and inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) has

been reported [13]. Pro-inflammatory cytokines like TNF- α , IL-1 β , and IL-6 have been shown to reduce renal erythropoietin (EPO) synthesis, desensitize erythroid progenitor cells to EPO, and inhibit erythropoietin receptor expression, resulting in impaired erythroid progenitor cell proliferation, reduced RBC maturation, and increased RDW [29].

Neurohormonal activation is recognized as one of the primary mechanisms driving the advancement of HF, and therapeutic inhibition of neurohormonal systems has emerged as the fundamental approach in modern pharmacotherapy for HF [30]. Erythrocyte progenitor cells are stimulated by the activation of neurohumoral and adrenergic systems, leading to reduced erythropoiesis and consequently, elevated RDW levels. Consequently, irrespective of the underlying cause, the activation of adrenergic and neurohumoral systems directly contributes to the increase in RDW [18,31].

HF often coexists with several comorbidities, among which renal dysfunction holds 312 particular importance. Cardiac and renal diseases intricately interact in both acute and 313 chronic settings, forming a complex bidirectional relationship. Pathophysiologically, 314 these conditions share common pathways, including inflammatory and direct cellular 315 316 immune-mediated mechanisms, stress-mediated and neurohormonal responses, metabolic and nutritional alterations such as bone and mineral disorders, changes in 317 hemodynamics and acid-base or fluid status, and the onset of anemia [32]. These 318 mechanisms contribute to explaining the renal impairment in HF patients. Additionally, 319

these mechanisms have also been implicated in increasing the RDW levels. In fact, our study observed an inverse correlation between RDW and Glomerular Filtration Rate (GFR) with r = -0.33 and p = 0.001, as depicted in **Fig 5**.

323 Predictive Ability of RDW for AHF Onset in HF Patients

Previous studies have shown that an increase in RDW is associated with an increased risk of hospitalization due to AHF [33,34]. The study by Ferreira et al. (2013) demonstrated that high RDW at admission is a predictor of slower diuretic response [35]. This provides us with a positive insight into RDW levels in AHF patients.

In our study, RDW demonstrated predictive capability for AHF in HF patients with 328 an AUC of 0.651, p < 0.001. The cutoff value of RDW in our study for predicting AHF 329 330 was 13.85%, with a sensitivity of 86.05% and specificity of 36.94%. Furthermore, the predictive value of RDW for AHF was comparable to hs-TnT, with no significant 331 difference in the AUC for predicting acute decompensated HF between these two 332 333 parameters (Fig 4). Hs-TnT elevation is common among patients with AHF [36]. There is no doubt that an increased troponin level predicts outcomes in AHF, and the greater 334 the elevation, the poorer the prognosis. It's crucial to recognize that cardiac troponin 335 indicates myocardial necrosis and is mainly employed for acute coronary syndrome 336 diagnosis, which may precipitate an AHF episode. In this context, alterations in troponin 337 levels over successive tests and the highest recorded level offer significant diagnostic 338

339	and prognostic insights [37,38]. We found that a cost-effective and widely available test
340	like RDW has an equivalent value to hs-TnT in predicting AHF.

Additionally, in our study, NT-proBNP exhibited a positive correlation with RDW 341 in HF patients (Fig 5). There is no disputing the value of NT-proBNP in predicting and 342 ruling out AHF. Numerous studies have demonstrated the excellent role of NT-proBNP 343 in HF patients, especially in AHF cases [39–42]. However, in developing countries, the 344 345 cost of performing NT-proBNP tests is prohibitively high and not available at primary healthcare facilities. Conversely, RDW is readily available and very inexpensive. Our 346 study indicates that the positive correlation between RDW and NT-proBNP could open 347 the door for the application of this index in primary healthcare facilities as well as in 348 developing countries like Vietnam. 349

350 Limitations of the study

Our study acknowledges several limitations. Firstly, relying solely on RDW 351 without concurrent inflammatory markers such as C-reactive protein and gamma-352 glutamyl transferase may result in an incomplete assessment of inflammatory status, 353 given RDW's susceptibility to various conditions. Additionally, we lacked control over 354 laboratory parameters linked to RDW variation and utilized a single blood analyzer 355 machine (Sysmex XS-1000i, Japan) without inter-machine comparison. Despite efforts 356 to mitigate selection bias through sequential sampling during routine HF visits, the 357 initial conduct of our study at a single hospital with a cross-sectional approach may limit 358

its generalizability. Moreover, the exclusivity of our study cohort to HF patients in central Vietnam further restricts generalization. Acknowledging the absence of serum iron ion data, a crucial confounder potentially affecting our results, future investigations will address this and consider the influence of unmeasured variables such as iron deficiency to enhance the study's robustness.

364 Conclusions

In the HF cohort, RDW levels were significantly higher compared to those in the non-HF cohort, and a positive correlation with NT-proBNP concentrations was observed. Additionally, RDW proved to be a valuable prognostic marker for AHF in HF patients. This study underscores the importance of further RDW research in HF to enhance understanding of its pathophysiology and improve risk assessment in HF management. Given its affordability and accessibility, RDW offers potential for application in resource-constrained environments.

372 Acknowledgments

373 Nil

374 **References**

Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global
 burden of heart failure: a comprehensive and updated review of epidemiology.
 Cardiovascular Research. 2023;118: 3272–3287. doi:10.1093/cvr/cvac013

378	2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB,
379	et al. Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart
380	Study. Circulation. 2002;106: 3068-3072. doi:10.1161/01.CIR.0000039105.49749.6F
381	3. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global,
382	regional, and national incidence, prevalence, and years lived with disability for 354
383	diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis
384	for the Global Burden of Disease Study 2017. The Lancet. 2018;392: 1789-1858.
385	doi:10.1016/S0140-6736(18)32279-7
386	4. Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, et
387	al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure
388	With Preserved Ejection Fraction. Journal of the American College of Cardiology.
389	2023;81: 1835–1878. doi:10.1016/j.jacc.2023.03.393
390	5. Ji X, Ke W. Red blood cell distribution width and all-cause mortality in
391	congestive heart failure patients: a retrospective cohort study based on the Mimic-III
392	database. Front Cardiovasc Med. 2023;10: 1126718. doi:10.3389/fcvm.2023.1126718
393	6. Hullin R, Barras N, Abdurashidova T, Monney P, Regamey J. Red cell
394	distribution width and prognosis in acute heart failure: ready for prime time! Intern
395	Emerg Med. 2019;14: 195-197. doi:10.1007/s11739-018-1995-7

396 7. Diez-Silva M, Dao M, Han J, Lim C-T, Suresh S. Shape and Biomechanical
397 Characteristics of Human Red Blood Cells in Health and Disease. MRS Bull. 2010;35:
382–388. doi:10.1557/mrs2010.571

399 8. Danese E, Lippi G, Montagnana M. Red blood cell distribution width and
400 cardiovascular diseases. J Thorac Dis. 2015;7: E402-411. doi:10.3978/j.issn.2072401 1439.2015.10.04

Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution
width: A simple parameter with multiple clinical applications. Critical Reviews in
Clinical Laboratory Sciences. 2015;52: 86–105. doi:10.3109/10408363.2014.992064

405 10. Feng G-H, Li H-P, Li Q-L, Fu Y, Huang R-B. Red blood cell distribution width
406 and ischaemic stroke. Stroke Vasc Neurol. 2017;2: 172–175. doi:10.1136/svn-2017407 000071

Wang L, Wang C, Wu S, Li Y, Guo W, Liu M. Red blood cell distribution width
is associated with mortality after acute ischemic stroke: a cohort study and systematic
review. Ann Transl Med. 2020;8: 81–81. doi:10.21037/atm.2019.12.142

411 12. Gu F, Wu H, Jin X, Kong C, Zhao W. Association of red cell distribution width
412 with the risk of 3-month readmission in patients with heart failure: A retrospective
413 cohort study. Front Cardiovasc Med. 2023;10: 1123905.
414 doi:10.3389/fcvm.2023.1123905

27

13. Xanthopoulos A, Giamouzis G, Dimos A, Skoularigki E, Starling R, Skoularigis 415 J, et al. Red Blood Cell Distribution Width in Heart Failure: Pathophysiology, 416 JCM. Prognostic Role, Controversies and Dilemmas. 2022;11: 1951. 417 418 doi:10.3390/jcm11071951

419 14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.
420 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of
421 acute and chronic heart failure. European Heart Journal. 2023;44: 3627–3639.
422 doi:10.1093/eurheartj/ehad195

Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al.
Guidelines for Performing a Comprehensive Transthoracic Echocardiographic
Examination in Adults: Recommendations from the American Society of
Echocardiography. Journal of the American Society of Echocardiography. 2019;32: 1–
64. doi:10.1016/j.echo.2018.06.004

428 16. Maynard RD, Korpi-Steiner N, Cotten SW. Concordance of Chronic Kidney
429 Disease Stage and Metformin Management Using CKD-EPI 2021 Race-Free Equation

430 vs CKD-EPI 2009 Equation to Estimate Glomerular Filtration Rate. Clinical Chemistry.

431 2023;69: 202–204. doi:10.1093/clinchem/hvac195

432 17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating

433 characteristic curves derived from the same cases. Radiology. 1983;148: 839–843.

434 doi:10.1148/radiology.148.3.6878708

28

18. Celik A, Koc F, Kadi H, Ceyhan K, Erkorkmaz U, Burucu T, et al. Relationship
between red cell distribution width and echocardiographic parameters in patients with
diastolic heart failure. The Kaohsiung J of Med Scie. 2012;28: 165–172.
doi:10.1016/j.kjms.2011.06.024

439 19. Dai Y, Konishi H, Takagi A, Miyauchi K, Daida H. Red cell distribution width
440 predicts short- and long-term outcomes of acute congestive heart failure more
441 effectively than hemoglobin. Experimental and Therapeutic Medicine. 2014;8: 600–
442 606. doi:10.3892/etm.2014.1755

20. 443 Oh J, Kang S-M, Hong N, Choi J-W, Lee S-H, Park S, et al. Relation Between 444 Red Cell Distribution Width With Echocardiographic Parameters in Patients With Acute Failure. Failure. Heart Journal of Cardiac 2009;15: 445 517-522. doi:10.1016/j.cardfail.2009.01.002 446

447 21. Lippi G, Turcato G, Cervellin G, Sanchis-Gomar F. Red blood cell distribution
448 width in heart failure: A narrative review. WJC. 2018;10: 6. doi:10.4330/wjc.v10.i2.6

449 22. Bekler A, Tenekecioglu E, Erbag G, Temiz A, Altun B, Barutcu A, et al.
450 Relationship between red cell distribution width and long-term mortality in patients with
451 non-ST elevation acute coronary syndrome. Anatol J Cardiol. 2015;15: 634–639.
452 doi:10.5152/akd.2014.5645

453 23. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red
454 cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and
455 chromatin modifications. Blood. 2011;118: 6258–6268. doi:10.1182/blood-2011-07456 356006

457 24. Ananthaseshan S, Bojakowski K, Sacharczuk M, Poznanski P, Skiba DS, Prahl
458 Wittberg L, et al. Red blood cell distribution width is associated with increased
459 interactions of blood cells with vascular wall. Sci Rep. 2022;12: 13676.
460 doi:10.1038/s41598-022-17847-z

461 25. Miglio A, Valente C, Guglielmini C. Red Blood Cell Distribution Width as a
462 Novel Parameter in Canine Disorders: Literature Review and Future Prospective.
463 Animals. 2023;13: 985. doi:10.3390/ani13060985

464 26. Joosse H-J, Van Oirschot BA, Kooijmans SAA, Hoefer IE, Van Wijk RAH,

465 Huisman A, et al. In-vitro and in-silico evidence for oxidative stress as drivers for RDW.

466 Sci Rep. 2023;13: 9223. doi:10.1038/s41598-023-36514-5

467 27. Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino468 Teixeira A, Sousa T. Inflammation in Human Heart Failure: Major Mediators and

469 Therapeutic Targets. Front Physiol. 2021;12: 746494. doi:10.3389/fphys.2021.746494

470 28. Khedar M, Sharma DK, Ola V. Red blood cell distribution width - A novel marker
471 of inflammation and predictor of complications and outcomes among surgically

472	managed	patients.	Formosan	Journal	of	Surgery.	2021;54:	130–134.
473	doi:10.410							

Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red 29. 474 cell distribution width in heart failure: Prediction of clinical events and relationship with 475 markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. 476 American Heart Journal. 2009;158: 659-666. doi:10.1016/j.ahj.2009.07.024 477 30. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced 478 ejection fraction. Nat Rev Cardiol. 2017;14: 30-38. doi:10.1038/nrcardio.2016.163 479 Contreras Gutiérrez VH. Red cell distribution width: A marker of in-hospital 31. 480 mortality in ST-segment elevation myocardial infarction patients? Revista Médica del 481 Hospital General de México. 2017;80: 165–169. doi:10.1016/j.hgmx.2016.10.001 482 Schefold JC, Filippatos G, Hasenfuss G, Anker SD, Von Haehling S. Heart failure 32. 483 and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev 484 Nephrol. 2016;12: 610-623. doi:10.1038/nrneph.2016.113 485 486 33. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of 487 the American College of Cardiology. 2007;50: 40-47. doi:10.1016/j.jacc.2007.02.067 488 Allen LA, Felker GM, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, et al. 34. 489 Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic 490

491 Marker in Heart Failure. Journal of Cardiac Failure. 2010;16: 230–238.
492 doi:10.1016/j.cardfail.2009.11.003

493 35. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H.
494 Tailoring diuretic therapy in acute heart failure: insight into early diuretic response
495 predictors. Clin Res Cardiol. 2013;102: 745–753. doi:10.1007/s00392-013-0588-8

496 36. Newby LK. High-Sensitivity Troponin in Acute Heart Failure Triage: Tacit but
497 Not Confirmed. Circ: Heart Failure. 2019;12: e006241.
498 doi:10.1161/CIRCHEARTFAILURE.119.006241

Wettersten N, University of California San Diego, Maisel A, Veterans Affairs 37. 499 San Diego Healthcare System, La Jolla, CA, USA. Role of Cardiac Troponin Levels in 500 Heart Failure. Failure 501 Acute Cardiac Review. 2015;1: 102. doi:10.15420/cfr.2015.1.2.102 502

38. Ledwoch J, Kraxenberger J, Krauth A, Schneider A, Leidgschwendner K,
Schneider V, et al. Prognostic impact of high-sensitive troponin on 30-day mortality in
patients with acute heart failure and different classes of left ventricular ejection fraction.
Heart Vessels. 2022;37: 1195–1202. doi:10.1007/s00380-022-02026-x

39. Richards AM, Christchurch Heart Institute, University of Otago, Christchurch,
New Zealand, Cardiovascular Research Institute, National University of Singapore,

32

- 509 Singapore. Biomarkers In Acute Heart Failure Cardiac And Kidney. Cardiac Failure
- 510 Review. 2015;1: 107. doi:10.15420/cfr.2015.1.2.107
- 511 40. Adamo M, Pagnesi M, Mebazaa A, Davison B, Edwards C, Tomasoni D, et al.
- 512 NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
- 513 European Heart Journal. 2023;44: 2947–2962. doi:10.1093/eurheartj/ehad335
- 514 41. Singhal AK, Singh G, Singh S, Karunanand B, Agrawal S. Role of Pro-BNP in
- 515 predicting outcome in acute heart failure patient presenting to a medical emergency: An
- 516 observational study from North India. Journal of Family Medicine and Primary Care.
- 517 2023;12: 3156–3159. doi:10.4103/jfmpc.jfmpc 853 23
- 518 42. Boehmer JP, Nair DG, Wen G, An Q, Thakur PH, Gardner RS. HeartLogic
- 519 Performs as Well as NT-proBNP to Rule out Acute Heart Failure at Point of Care.
- 520 Journal of Cardiac Failure. 2019;25: S17–S18. doi:10.1016/j.cardfail.2019.07.052

















